Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
We are a clinical-stage pharmaceutical company developing treatments for cannabis-induced toxicity, such as acute cannabis-induced toxicity in children, acute cannabinoid intoxication ( ACI ) and the broader landscape of acute cannabis-induced conditions. Our lead product candidate, selonabant (formerly ANEB-001), is intended to rapidly reverse the negative effects of cannabis-induced …
$0.33
$0.03 (-7.22%)
Price from 3 days ago
ROIC dropped from -913.77% to -24224.71%, capital efficiency is deteriorating.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$8M
▼ -3.5% YoY
Op. Margin
—
ROIC
-67.22%
▼ -23310.9pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$6M
▲ +21.5% YoY
Net Debt
-$9M
Net Cash Position
Cash & Equiv.
$9M
Continue Research
SourceComputed from the 10-Q filed 12 Feb 2026, covering the period ending 31 Dec 2025, as reported to the SEC. Data last refreshed 12 Feb 2026. How this is calculated.
Price from market data, last close as of 17 Sept 2026. Fiscal year ends Jun. Sector medians are approximate S&P 500 benchmarks and update periodically.